Enzyme-Linked Immunosorbent Assays Market Size, Share and Global Trend By Test Type (Direct ELISA, Sandwich ELISA, Competitive ELISA, Reverse ELISA), By Application (Immunology, Inflammation, Infectious Diseases, Cancer, Protein Quantification), By End User (Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Research & Academic Institutions), and Regional Forecast, 2024-2032

Enzyme-Linked Immunosorbent Assays (ELISA) is a commonly used analytical biochemistry assay used for qualitatively assessing or quantitatively measuring the presence, amount, or functional activity of an analyte. In ELISA, an antigen must be immobilized on a solid surface and then complexed with an antibody that is connected to an enzyme. The most vital element of the detection strategy is an extremely specific antibody-antigen interaction. ELISA can be classified into four types: Direct ELISA, Sandwich ELISA, Competitive ELISA, and Reverse ELISA.

ELISA has a variety of application such as the evaluation of the HIV or West Nile Virus and for the detection of food allergens including milk, peanuts, walnuts, almonds, and eggs. The advantages of Enzyme-Linked Immunosorbent Assays (ELISA) are its high sensitivity and strong specificity compared to other tests such as radioimmune assay (RIA). The World Health Organization (WHO) estimated that there were an estimated 36.9 million people living with HIV at the end of 2017 with approximately 1.8 million people becoming newly infected in 2017 worldwide.

Diagnosis of HIV infection is generally undertaken through rapid diagnostic tests (RDTs), which detect the presence or absence of HIV antibodies. The results from the tests are obtained the same day and often help in the early commencement of the treatment. These factors are expected to positively drive the market and contribute considerably to the growth of the market.

One of the key drivers of the growth in the market is the increasing prevalence of the infectious and chronic diseases contributing to the rapid growth of the market coupled with the technological advancements in ELISA. Another factor contributing to the rapid growth of the market is the possibility of early detection with the ELISA tests and also the growing demand for in vitro diagnostics.

The factor that is expected to inhibit the growth of the market is the disadvantage of the tests only being applied to liquid samples. Other inhibiting factors for the market can be very specific to particular enzymes, expensive commercially available kits and the measurement of enzyme activity can be complex.

Key Players Covered

Some of the major companies that are present in the global Enzyme-Linked Immunosorbent Assays (ELISA) market are Thermo Fisher Scientific. Inc., Bio-Rad Laboratories, Inc., Ortho-Clinical Diagnostics, ZEUS Scientific, Inc., BD, ALPCO, bioMérieux SA and other players.

SEGMENTATION

At present, direct ELISA accounts for the largest proportion of the market and this is not expected to change because it is one of the most used test types in ELISA and it is less prone to error because the number of steps required in this type of ELISA is the fewest.

Key Insights

• Regulatory Scenario by Key Countries
• Overview of Advancements in Research & Development of ELISA
• Overview of Cost Analysis of ELISA in Comparison to Other Tests
• Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions
• New Product Launches

Regional Analysis

The global Enzyme-Linked Immunosorbent Assays (ELISA) market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for Enzyme-Linked Immunosorbent Assays (ELISA) at present and they are expected to account for a large proportion of the market in the forecast period as well. This is because due to the ongoing R&D initiatives and the increasing sophistication of the ELISA, resulting in greater usage of the tests. In the Asia Pacific region, Japan is expected to provide the largest market opportunity. This is because Japan has a highly developed healthcare system and the healthcare expenditure is higher owing to the developed insurance scenario.

Key Industry Developments

• In March 2019, due to the recent advances in ELISA, a University of Pennsylvania and University of Maryland research team were able to identify spontaneous preterm birth clues in cervicovaginal microbiome, through an ELISA test
• In January 2019, The Native Antigen Company announced the launch of new Zika immunoassays called the NS1 ELISA assay which is equipped with unprecedented sensitivity and specificity across a range of biological samples
• In March 2018, BARD1 Life Sciences, U.S-based Science Research Company is anticipated to move for the commercialization of their BARD1-Ovarian blood based ELISA test, for the early determination of ovarian cancer.